TW202200146A - 使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法 - Google Patents

使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法 Download PDF

Info

Publication number
TW202200146A
TW202200146A TW110112988A TW110112988A TW202200146A TW 202200146 A TW202200146 A TW 202200146A TW 110112988 A TW110112988 A TW 110112988A TW 110112988 A TW110112988 A TW 110112988A TW 202200146 A TW202200146 A TW 202200146A
Authority
TW
Taiwan
Prior art keywords
salt
day
once
compound
administered
Prior art date
Application number
TW110112988A
Other languages
English (en)
Chinese (zh)
Inventor
平井洋
松岡和明
三浦晃敬
Original Assignee
日商大鵬藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大鵬藥品工業股份有限公司 filed Critical 日商大鵬藥品工業股份有限公司
Publication of TW202200146A publication Critical patent/TW202200146A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110112988A 2020-04-10 2021-04-09 使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法 TW202200146A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020071355 2020-04-10
JP2020-071355 2020-04-10

Publications (1)

Publication Number Publication Date
TW202200146A true TW202200146A (zh) 2022-01-01

Family

ID=78024029

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110112988A TW202200146A (zh) 2020-04-10 2021-04-09 使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法

Country Status (5)

Country Link
US (1) US20230165862A1 (https=)
EP (1) EP4134081A4 (https=)
JP (1) JP7805285B2 (https=)
TW (1) TW202200146A (https=)
WO (1) WO2021206167A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116768903A (zh) * 2023-06-20 2023-09-19 河北康泰药业有限公司 一种吡咯并嘧啶衍生物及其制备方法、药物组合物和应用
CN116789673A (zh) * 2023-06-20 2023-09-22 河北康泰药业有限公司 一种吡咯并嘧啶衍生物及其制备方法、药物组合物和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
ZA200703912B (en) 2004-10-20 2008-09-25 Serono Lab 3-arylamino pyridine derivatives
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
AU2014291161B2 (en) * 2013-07-18 2018-04-26 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of FGFR inhibitor
JP6860919B2 (ja) * 2015-11-19 2021-04-21 国立大学法人金沢大学 間葉系ｋｒａｓ変異型がん治療剤
EP3424505A4 (en) * 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
KR102811888B1 (ko) * 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116768903A (zh) * 2023-06-20 2023-09-19 河北康泰药业有限公司 一种吡咯并嘧啶衍生物及其制备方法、药物组合物和应用
CN116789673A (zh) * 2023-06-20 2023-09-22 河北康泰药业有限公司 一种吡咯并嘧啶衍生物及其制备方法、药物组合物和应用

Also Published As

Publication number Publication date
JP7805285B2 (ja) 2026-01-23
WO2021206167A9 (ja) 2021-11-18
EP4134081A4 (en) 2024-05-01
US20230165862A1 (en) 2023-06-01
JPWO2021206167A1 (https=) 2021-10-14
EP4134081A1 (en) 2023-02-15
WO2021206167A1 (ja) 2021-10-14

Similar Documents

Publication Publication Date Title
TWI607754B (zh) 醫藥組合
EP4157465A2 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
CN110022900A (zh) 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
AU2020253054B2 (en) FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
US20230110113A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
US20260053761A1 (en) Use of thyromimetics for the treatment of cancer
JP7805285B2 (ja) ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法
AU2020297166A1 (en) Method for treating malignant tumor
JP2024502671A (ja) ピリド［１，２－ａ］ピリミジノン類似体の使用
Han et al. The combination of tetracyclines effectively ameliorates liver fibrosis via inhibition of EphB1/2
CN114728003A (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
CN121175049A (zh) 治疗包含非典型egfr突变的癌症的egfr抑制剂
TWI872311B (zh) 一種吡啶并[1,2-a]嘧啶酮類似物的應用
US20070135444A1 (en) Treatment of neuroblastoma
Healthyni et al. Potential use of lapatinib in the treatment of head and neck squamous cell carcinoma
Takeda et al. Targeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms
CN103635186A (zh) 包括d-普萘洛尔和其类似物的磷脂酸磷酸水解酶（pap）的抑制剂，单独或与地昔帕明组合用于治疗依赖于表皮生长因子受体（egfr）、其致癌变体和erbb/her家族其他成员的癌症
US20240010622A1 (en) Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis
JP2025500434A (ja) γサブユニットを標的とするミトコンドリアＡＴＰ阻害剤は転移を予防する
CN117479958A (zh) 用于治疗癌症的药物组合和药物组合物
HK40026870A (en) A pharmaceutical combination for the treatment of melanoma
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
TW202110447A (zh) 降低阿帕替尼臨床毒性的方法
TW201217341A (en) Receptor-type kinase modulator and methods of treating polycystic kidney disease
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma